The UK Ambassador to the UAE, Patrick Moody, has been reviewing the third phase of the COVID-19 vaccine clinical trials with the Abu Dhabi Health Services Company, SEHA.
The British Ambassador was given a tour of SEHA’s specialised centre for conducting the clinical trials at the Abu Dhabi Exhibition Centre, which is managed by the network’s expert medical practitioners.
He also received a briefing on the process, demonstrating its safety and effectiveness.
Developed by Sinopharm CNBG and G42 Healthcare, a subsidiary of G42 Group, the trials are a collaboration between the Department of Health - Abu Dhabi and SEHA.
They are part of the global effort to combat COVID-19 and have been overseen by the World Health Organisation and the UAE’s Ministry of Health and Prevention. Abu Dhabi.
Dr Marwan Al Kaabi, Acting Group Chief Operations Officer at SEHA, said, "As we continue delivering the COVID-19 vaccine to frontline healthcare professionals and ensure the protection of our community, we are pleased to share our progress with Ambassador Moody. "
Al Kaabi added, "The key to the success of the third phase of the clinical trials has been collaboration and support from Abu Dhabi’s ecosystem of partners, enabling the nation to play an integral in providing a vaccine to combat the novel coronavirus."
We were very pleased to welcome Her Majesty's Ambassador to the UAE, His Excellency Patrick Moody, at our specialized center for COVID-19 vaccine clinical trials at ADNEC.@ukinuae @PMoodyFCDO @ADNECGroup @ashot4humanity #SEHA #Healthcare #inAbuDhabi pic.twitter.com/RaaPrOtB36
— SEHA - شركة صحة (@SEHAHealth) November 19, 2020
Emirates, flydubai serve 19 million passengers over 7 years
Dubai Taxi beefs up fleet with more electric vehicles
UAE: Missions should monitor climate to reduce insecurity
COP29: Presidencies Troika calls for high climate ambitions
